Cannabinoid disposition in oral fluid after controlled vaporizer administration with and without alcohol

Forensic Toxicology

Volumn 33, Issue 2, 2015, Pages 260-278

  Hartman, Rebecca L ^a   Anizan, Sébastien ^a   Jang, Moonhee ^a,b   Brown, Timothy L ^c   Yun, Keming ^a,d   Gorelick, David A ^a,e   Milavetz, Gary ^c   Spurgin, Andrew ^c   Gaffney, Gary ^f   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b National Forensic Service   (South Korea)

^c UNIVERSITY OF IOWA   (United States)

^d SHANXI MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

Alcohol; Cannabis; On site; Oral Fluid; Vaporizer

Indexed keywords

ALCOHOL; CANNABIDIOL; CANNABINOID; CANNABINOL; CANNABIS; DRONABINOL; PLACEBO; TETRAHYDROCANNABINOLIC ACID;

ADULT; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; ARTICLE; BODY FLUID; BREATH ALCOHOL ANALYSIS; BREATH ALCOHOL ANALYZER; BREATH ANALYSIS; CANNABIS SMOKING; CONTROLLED STUDY; DRUG DISPOSITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; ORAL FLUID; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SMOKING; TIME OF LAST DETECTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VAPORIZATION; VAPORIZER; YOUNG ADULT;

CANNABIS;

EID: 84937521472     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-015-0269-6     Document Type: Article

References (65)

1. Lacey JH, Kelley-Baker T, Furr-Holden D, Voas RB, Romano E, Ramirez A, Brainard K, Moore C, Torres P, Berning A (2009) 2007 National roadside survey of alcohol and drug use by drivers: drug results. DOT HS 811 249 National Highway Traffic Safety Administration Office of Behavioral Safety Research, Washington, DC
2. Davey J, Leal N, Freeman J (2007) Screening for drugs in oral fluid: Illicit drug use and drug driving in a sample of Queensland motorists. Drug Alcohol Rev 26:301–307
3. Poulsen H, Moar R, Troncoso C (2012) The incidence of alcohol and other drugs in drivers killed in New Zealand road crashes 2004–2009. Forensic Sci Int 223:364–370
4. Hartman RL, Huestis MA (2013) Cannabis effects on driving skills. Clin Chem 59:478–492
5. Ramaekers JG, Robbe HWJ, O’Hanlon JF (2000) Marijuana, alcohol and actual driving performance. Hum Psychopharm 15:551–558
6. Ramaekers J, Kauert G, Theunissen E, Toennes S, Moeller M (2009) Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 23:266–277
7. Bosker WM, Theunissen EL, Conen S, Kuypers KP, Jeffery WK, Walls HC, Kauert GF, Toennes SW, Moeller MR, Ramaekers JG (2012) A placebo-controlled study to assess standardized field sobriety tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid. Psychopharmacology 223:439–446
8. Charlton SG, Starkey NJ (2013) Driver risk from blood alcohol levels between 50 mg/100 ml and 80 mg/100 ml. NZ Transport Agency Research Report Traffic and Road Safety Research Group. University of Waikato, Hamilton
9. Johnson MB, Kelley-Baker T, Voas RB, Lacey JH (2012) The prevalence of cannabis-involved driving in California. Drug Alcohol Depen 123:105–109
10. Rocky Mountain High Intensity Drug Trafficking Area (2013) The legalization of marijuana in Colorado: the impact 1:1–66
11. Bosker WM, Huestis MA (2009) Oral fluid testing for drugs of abuse. Clin Chem 55:1910–1931
12. Drummer OH (2006) Drug testing in oral fluid. Clin Biochem Rev 27:147–159
13. Wille SM, Di Fazio V, Toennes SW, van Wel JH, Ramaekers JG, Samyn N (2014) Evaluation of Δ9-tetrahydrocannabinol detection using DrugWipe5S screening and oral fluid quantification after Quantisal collection for roadside drug detection via a controlled study with chronic cannabis users. Drug Test Anal. doi:10.1002/dta.1660
14. Bogstrand ST, Gjerde H (2014) Which drugs are associated with highest risk for being arrested for driving under the influence? A case–control study. Forensic Sci Int 240:21–28
15. Kelley-Baker T, Moore C, Lacey JH, Yao J (2014) Comparing drug detection in oral fluid and blood: data from a national sample of nighttime drivers. Traffic Inj Prev 15:111–118
16. Substance Abuse and Mental Health Services Administration (SAMHSA) (2004) Notice of proposed revisions to the mandatory guidelines for federal workplace drug testing programs. Fed Regist 69:19673–19732
17. Pil K, Raes E, Van den Neste T, Verstraete A (2007) Toxicological analyses in the DRUID epidemiological studies: analytical methods, target analytes and analytical cut-offs. Paper presented at the The European Integrated Project DRUID 2007
18. Baggio S, Deline S, Studer J, Mohler-Kuo M, Daeppen JB, Gmel G (2014) Routes of administration of cannabis used for nonmedical purposes and associations with patterns of drug use. J Adolesc Health 54:235–240
19. Huestis MA, Henningfield JE, Cone EJ (1992) Blood cannabinoids I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16:276–282
20. Lee D, Schwope DM, Milman G, Barnes AJ, Gorelick DA, Huestis MA (2012) Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem 58:748–756
21. Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ (1992) Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther 52:31–41
22. Pomahacova B, Van der Kooy F, Verpoorte R (2009) Cannabis smoke condensate III: the cannabinoid content of vaporised Cannabis sativa. Inhal Toxicol 21:1108–1112
23. Fischedick J, Van Der Kooy F, Verpoorte R (2010) Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor. Chem Pharm Bull (Tokyo) 58:201–207
24. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL (2007) Vaporization as a smokeless cannabis delivery system: a pilot study. Clinic Pharmacol Ther 82:572–578
25. Zuurman L, Roy C, Schoemaker R, Hazekamp A, den Hartigh J, Bender J, Verpoorte R, Pinquier J, Cohen A, van Gerven J (2008) Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol 22:707–716
26. Van Dam NT, Earleywine M (2010) Pulmonary function in cannabis users: support for a clinical trial of the vaporizer. Int J Drug Policy 21:511–513
27. Earleywine M, Barnwell SS (2007) Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduct J 4:11
28. Toennes SW, Kauert GF, Steinmeyer S, Moeller MR (2005) Driving under the influence of drugs—evaluation of analytical data of drugs in oral fluid, serum and urine, and correlation with impairment symptoms. Forensic Sci Int 152:149–155
29. Musshoff F, Hokamp EG, Bott U, Madea B (2014) Performance evaluation of on-site oral fluid drug screening devices in normal police procedure in Germany. Forensic Sci Int 238:120–124
30. Wille SM, Samyn N, Ramírez-Fernández Mdel M, De Boeck G (2010) Evaluation of on-site oral fluid screening using Drugwipe-5+, RapidSTAT and Drug Test 5000 for the detection of drugs of abuse in drivers. Forensic Sci Int 198:2–6
31. Toennes SW, Schneider K, Wunder C, Kauert GF, Moeller MR, Theunissen EL, Ramaekers JG (2013) Influence of ethanol on the pharmacokinetic properties of Δ9-tetrahydrocannabinol in oral fluid. J Anal Toxicol 37:152–158
32. Desrosiers NA, Lee D, Schwope DM, Milman G, Barnes AJ, Gorelick DA, Huestis MA (2012) On-site test for cannabinoids in oral fluid. Clin Chem 58:1418–1425
33. Desrosiers NA, Milman G, Mendu DR, Lee D, Barnes AJ, Gorelick DA, Huestis MA (2014) Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices. Anal Bioanal Chem 406:4117–4128
34. Lee D, Milman G, Schwope DM, Barnes AJ, Gorelick DA, Huestis MA (2012) Cannabinoid stability in authentic oral fluid after controlled cannabis smoking. Clin Chem 58:1101–1109
35. Milman G, Barnes AJ, Lowe RH, Huestis MA (2010) Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J Chromatogr A 1217:1513–1521
36. Welling PG, Lyons L, Elliott R, Amidon GL (1977) Pharmacokinetics of alcohol following single low doses to fasted and nonfasted subjects. J Clin Pharmacol 17:199–206
37. Wilkinson PK (1980) Pharmacokinetics of ethanol: a review. Alcoholism Clin Exp Res 4:6–21
38. Newmeyer MN, Desrosiers NA, Lee D, Mendu DR, Barnes AJ, Gorelick DA, Huestis MA (2014) Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Test Anal 6:1002–1010
39. Anizan S, Milman G, Desrosiers N, Barnes AJ, Gorelick DA, Huestis MA (2013) Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. Anal Bioanal Chem 405:8451–8461
40. Bergamaschi M, Queiroz R, Zuardi A, Crippa J (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6:237–249
41. Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schroder N, Nardi AE, Martin-Santos R, Hallak JEC, Zuardi AW, Crippa JAS (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36:1219–1226
42. Szaflarski JP, Martina Bebin E (2014) Cannabis, cannabidiol, and epilepsy—from receptors to clinical response. Epilepsy Behav. doi:10.1016/j.yebeh.2014.08.135
43. Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF (2010) Pharmacokinetic properties of Δ9-tetrahydrocannabinol in oral fluid of occasional and chronic users. J Anal Toxicol 34:216–221
44. Malouff JM, Rooke SE, Copeland J (2014) Experiences of marijuana-vaporizer users. Subst Abus 35:127–128
45. Lee D, Vandrey R, Mendu DR, Murray JA, Barnes AJ, Huestis MA (2014) Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking. Drug Test Anal. doi:10.1002/dta.1718
46. Huestis MA, Cone EJ (2004) Relationship of Δ9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol 28:394–399
47. Milman G, Schwope DM, Gorelick DA, Huestis MA (2012) Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis. Clin Chim Acta 413:765–770
48. Verstraete AG (2005) Oral fluid testing for driving under the influence of drugs: history, recent progress and remaining challenges. Forensic Sci Int 150:143–150
49. Moore C, Coulter C, Uges D, Tuyay J, van der Linde S, van Leeuwen A, Garnier M, Orbita J Jr (2011) Cannabinoids in oral fluid following passive exposure to marijuana smoke. Forensic Sci Int 212:227–230
50. Milman G, Barnes AJ, Schwope DM, Schwilke EW, Darwin WD, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA (2010) Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem 56:1261–1269
51. Fabritius M, Chtioui H, Battistella G, Annoni JM, Dao K, Favrat B, Fornari E, Lauer E, Maeder P, Giroud C (2013) Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. Anal Bioanal Chem 405:9791–9803
52. Lee D, Milman G, Barnes AJ, Goodwin RS, Hirvonen J, Huestis MA (2011) Oral fluid cannabinoids in chronic, daily cannabis smokers during sustained, monitored abstinence. Clin Chem 57:1127–1136
53. Maseda C, Hama K, Fukui Y, Matsubara K, Takahashi S, Akane A (1986) Detection of Δ9-THC in saliva by capillary GC/ECD after marihuana smoking. Forensic Sci Int 32:259–266
54. Lukas SE, Benedikt R, Mendelson JH, Kouri E, Sholar M, Amass L (1992) Marihuana attenuates the rise in plasma ethanol levels in human subjects. Neuropsychopharmacology 7:77–81
55. Abalo R, Vera G, Lopez-Perez AE, Martinez-Villaluenga M, Martin-Fontelles MI (2012) The gastrointestinal pharmacology of cannabinoids: focus on motility. Pharmacology 90:1–10
56. Izzo AA, Sharkey KA (2010) Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Therapeut 126:21–38
57. Dubowski KM (1985) Absorption, distribution and elimination of alcohol: highway safety aspects. J Stud Alcohol 10:98–108
58. Laloup M, del Mar Ramirez Fernandez M, Wood M, De Boeck G, Maes V, Samyn N (2006) Correlation of Δ9-tetrahydrocannabinol concentrations determined by LC-MS-MS in oral fluid and plasma from impaired drivers and evaluation of the on-site Dräger DrugTest. Forensic Sci Int 161:175–179
59. Logan BK, Mohr AL, Talpins SK (2014) Detection and prevalence of drug use in arrested drivers using the Dräger Drug Test 5000 and Affiniton DrugWipe oral fluid drug screening devices. J Anal Toxicol 38:444–450
60. Gieringer D, St. Laurent J, Goodrich S (2004) Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannab Therapeut 4:7–27
61. Chemic Laboratories (2003) Evaluation of Volcano vaporizer for the efficient emission of THC, CBD, CBN and the significant reduction and/or elimination of polynuclear-aromatic (PNA) analytes resultant of pyrolysis. Report No. 1311619-0103-2563, Canton; pp 1–57
62. Henningfield JE, Fant RV, Radzius A, Frost S (1999) Nicotine concentration, smoke pH and whole tobacco aqueous pH of some cigar brands and types popular in the United States. Nicotine Tob Res 1:163–168
63. Hazekamp A (2010) The Volcano Medic cannabis vaporizer: optimal temperature for single-dose administration of 100 mg cannabis or 10 mg dronabinol. LabAssistent Phytochemical Services Project No. 2010-003c, Leiden; pp 1–13
64. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R (2006) Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 95(6):1308–1317
65. Drummer OH (2005) Review: pharmacokinetics of illicit drugs in oral fluid. Forensic Sci Int 150:133–142